Ligand Pharmaceuticals Incorporated (LGND) P/E Ratio History
Historical price-to-earnings valuation from 2007 to 2025
Loading P/E history...
LGND Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a price-to-earnings ratio of -956.0x, with a stock price of $210.33 and trailing twelve-month earnings per share of $2.41.
The current P/E is 2501% below its 5-year average of 39.8x. Over the past five years, LGND's P/E has ranged from a low of 3.6x to a high of 88.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, LGND trades at a 4383% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, LGND trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LGND DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LGND P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9Lowest | 0.67 | +817%Best | |
| $5B | 16.7 | 0.44Best | +8% | |
| $22B | 27.9 | 3.95 | -6% | |
| $490M | 28.3 | 2.12 | +188% | |
| $358B | 85.5 | - | -1% | |
| $151B | 19.5 | - | -4% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
LGND Historical P/E Data (2007–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $177.14 | $2.07 | 85.6x | -97% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $100.09 | $2.51 | 39.9x | -99% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $84.26 | $2.16 | 39.0x | -99% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $73.10 | $5.17 | 14.1x | -100% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $71.42 | $2.75 | 26.0x | -99% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $59.92 | $0.68 | 88.1x | -97% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $72.10 | $1.44 | 50.1x | -98% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $73.56 | $1.26 | 58.4x | -98% |
| FY2022 Q1 | $112.49 | $1.38 | 81.5x | -97% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $154.46 | $3.34 | 46.2x | -98% |
| FY2021 Q3 | $139.32 | $3.99 | 34.9x | -99% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $131.19 | $2.77 | 47.4x | -98% |
Average P/E for displayed period: 3007.1x
See LGND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LGND Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LGND vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLGND — Frequently Asked Questions
Quick answers to the most common questions about buying LGND stock.
Is LGND stock overvalued or undervalued?
LGND trades at -956.0x P/E, below its 5-year average of 39.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does LGND's valuation compare to peers?
Ligand Pharmaceuticals Incorporated P/E of -956.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is LGND's PEG ratio?
LGND PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2007-2025.